First approval of a conjugate vaccine that helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia, 1,2,3,4,5,6,7 including seven responsible for 40% of pneumococcal disease cases and deaths in the U.S. Helps protect against more serotypes of pneumococcal disease than any other conjugate vaccine Builds on Pfizer’s more than 20-year legacy and innovation in .
Pfizer’s pneumococcal vaccine approved by the FDA for adults aged 18 years or older
Vaccine helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia
Pfizer’s PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) has been approved by the US Food and Drug Administration (FDA) for the prevention of invasive disease and pneumonia in adults aged 18 years and older. The vaccine helps protect against 20 streptococcus pneumoniae (pneumococcus) serotypes.
Recommendations on the safe and appropriate use of pneumococcal vaccines in adults are expected to be discussed and updated when the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) meets in October.
Read the latest Sickle Cell Disease headlines - updated 24/7/365. We link to the best sources from around the world. Get the latest on Sickle Cell Disease.
WASHINGTON (dpa-AFX) - Protalix BioTherapeutics, Inc. (PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., reported positive initial top line results from the Phase 3 study